Immutep Stock Gains on Encouraging Data from Early-Stage Solid Cancer Studies

  • Immutep Limited IMMP has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncology's 2021 Annual Meeting.
  • Data from Phase I INSIGHT trial evaluating eftilagimod alpha combined with Pfizer Inc's PFE Bavencio (avelumab) in advanced solid tumors showed:
    • Five patients showed partial response (PR) as the best response, one stable disease with clinical progression (all but one of these patients are still alive).
    • Five disease progressions, one clinical progression were also reported.
    • No dose-limiting toxicities (DLTs) occurred. Ten serious adverse events (SAEs) were reported, none of them considered causally related.
  • Data from Phase 2 trial of eftilagimod alpha combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) in metastatic non-small cell lung carcinoma.
    • The objective response rate was 27%, with a median progression-free survival (PFS) of 8.2 months, while median overall survival (OS) was not yet reached.
    • Two patients discontinued treatment due to adverse reactions.
  • Data from Phase 2 trial of eftilagimod alpha in combination with pembrolizumab in metastatic second-line squamous head and neck carcinoma.
    • 35 patients were evaluated for response (cut-off Jan 2021), with 4 pts showing a complete response, CR, seven patients partial response, three patients with stable disease.
    • 31.4% of ORR was reported with a disease control rate of 40%.
    • Median PFS was 2.1 months, and 35 % were progression-free at six months. Median OS was 12.6 months.
    • No adverse reactions were leading to treatment discontinuation.
  • Price Action: IMMP shares are up 16.3% at $4.79 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefscancerPhase 1 TrialSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!